Fortis Healthcare seeks shareholder nod for Mohd Shahazwan's director appointment
Fortis Healthcare is seeking shareholder approval to appoint Mr. Mohd Shahazwan Bin Mohd Harris as a Non-Independent & Non-Executive Director. The postal ballot process is underway, with voting open from December 24, 2025, to January 22, 2026. Mr. Harris brings over 25 years of experience in investments and strategy.
The appointment of a new director can influence the company's strategic direction and governance, making it a medium-impact event for stakeholders.
The announcement is a routine corporate action to appoint a new director and requires shareholder approval. It does not contain any financial performance data or significant business developments that would sway sentiment.
Fortis Healthcare Limited is seeking shareholder approval for the appointment of Mr. Mohd Shahazwan Bin Mohd Harris as a Non-Independent & Non-Executive Director. The company has initiated the postal ballot process, sending out notices to its members on December 23, 2025, for their assent or dissent on this proposal.
The appointment of Mr. Mohd Shahazwan Bin Mohd Harris (DIN: 08465456) is proposed as he was appointed as an Additional Director by the Board of Directors effective December 19, 2025. This appointment requires shareholder ratification as per SEBI regulations. Mr. Mohd Shahazwan Bin Mohd Harris brings over 25 years of experience in investments, mergers and acquisitions, portfolio and asset management, corporate strategy, and restructuring. His qualifications include an MBA from MIT and an MSc from Imperial College.
Members can cast their votes either through a postal ballot form or via remote e-voting. The remote e-voting period commences on December 24, 2025, at 9:00 a.m. IST and concludes on January 22, 2026, at 5:00 p.m. IST. Ballots received after the deadline will not be considered. The results of the postal ballot are expected to be declared by January 27, 2026.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.